High-dose Wegovy data: Social media erupted over Novo Nordisk's revelation that early responders on the 7.2 mg Wegovy dose shed nearly 28% of body weight after 72 weeks, with an average loss of 21% mostly from fat mass. Enthusiasts argue this bolsters Novo Nordisk's edge in the intensifying obesity drug rivalry. The findings, presented at a major congress, signal robust pipeline momentum.
Partnership surge: Conversations spotlight the Wegovy partnership with telehealth providers, fulfilling over 125,000 orders swiftly and eyeing 100,000 monthly subscriber adds. Healthcare rotation lifts NVO alongside peers amid market turbulence. Users forecast explosive growth as branded GLP-1s funnel users into broader ecosystems.
Market optimism: Celebrity weight loss tales tie into trial successes, fueling bullish chatter despite some data scrutiny. Benefits for women across menopause stages, slashing risks like migraines, broaden appeal. Pipeline expansions and next-gen launches keep long-term prospects vivid.
Note: This discussion summary was generated from an AI condensation of post data.
Novo Nordisk Revenue
Novo Nordisk had revenues of $15B in Q1 2026.
You can track NVO financials on Quiver Quantitative's NVO stock page.
You can access data on NVO stock through the Quiver Quantitative API.
Novo Nordisk Hedge Fund Activity
We have seen 543 institutional investors add shares of Novo Nordisk stock to their portfolio, and 837 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL INTERNATIONAL INVESTORS removed 6,502,318 shares (-36.7%) from their portfolio in Q4 2025, for an estimated $330,837,939
- PRICE T ROWE ASSOCIATES INC /MD/ added 4,836,285 shares (+99.7%) to their portfolio in Q4 2025, for an estimated $246,070,180
- VOLORIDGE INVESTMENT MANAGEMENT, LLC added 4,302,126 shares (+851.6%) to their portfolio in Q4 2025, for an estimated $218,892,170
- CITADEL ADVISORS LLC added 4,278,889 shares (+136.6%) to their portfolio in Q4 2025, for an estimated $217,709,872
- FMR LLC removed 4,058,066 shares (-28.8%) from their portfolio in Q4 2025, for an estimated $206,474,398
- FAYEZ SAROFIM & CO removed 3,118,838 shares (-42.4%) from their portfolio in Q4 2025, for an estimated $158,686,477
- DAVENPORT & CO LLC removed 2,122,035 shares (-96.2%) from their portfolio in Q1 2026, for an estimated $76,085,564
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Novo Nordisk Analyst Ratings
Wall Street analysts have issued reports on $NVO in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Goldman Sachs issued a "Buy" rating on 11/28/2025
To track analyst ratings and price targets for Novo Nordisk, check out Quiver Quantitative's $NVO forecast page.
Novo Nordisk Price Targets
Multiple analysts have issued price targets for $NVO recently. We have seen 3 analysts offer price targets for $NVO in the last 6 months, with a median target of $46.0.
Here are some recent targets:
- James Quigley from Goldman Sachs set a target price of $41.0 on 03/02/2026
- An analyst from CICC set a target price of $73.5 on 01/09/2026
- Evan David Seigerman from BMO Capital set a target price of $46.0 on 11/25/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
